Novavax Inc vs Carparts.Com Inc — how do they compare? Novavax Inc trades at $11.11 (market cap $1.85B), while Carparts.Com Inc trades at $8.59 (market cap $67.00M). The key difference: Novavax Inc is far larger — about 27.6× Carparts.Com Inc's market cap, and Carparts.Com Inc is more actively traded (50,584 versus 8,362,562). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Carparts.Com Inc for 45 Days on average.
| NVAX | PRTS | |
|---|---|---|
Market Cap | $1.85B | $67.00M |
Volume | 8,362,562 | 50,584 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $10.00 |
52-Week Low | $6.22 | $3.88 |
Typical Hold Time | 59 Days | 45 Days |
Enterprise Value | $1.43B | $79.96M |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
CarParts.com (PRTS) trades at $8.59, down 0.23% with a bullish technical outlook. The company shows improving quarterly earnings beats but faces fundamental challenges with negative profitability metrics. Recent news highlights the company's focus on leveraging proprietary data as a competitive advantage. Technical indicators show strong moving average support while oscillators remain neutral.
The stock presents a mixed picture with strong analyst support (60% buy ratings) but persistent negative earnings. Investment opportunity lies in continued operational improvements and data-driven strategy execution, while risks include sustained negative cash flow and competitive pressures in the auto parts e-commerce sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →